Identification of novel mechanisms of silymarin on the carbon tetrachloride-induced liver fibrosis in mice by nuclear factor-κB bioluminescent imaging-guided transcriptomic analysis

Food and Chemical Toxicology

Volumn 50, Issue 5, 2012, Pages 1568-1575

  Li, Chia Cheng ^a   Hsiang, Chien Yun ^a   Wu, Shih Lu ^a   Ho, Tin Yun ^a,b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bioluminescent imaging; Cytochrome c oxidase; DNA microarray; Liver fibrosis; Nuclear factor B; Silymarin

Indexed keywords

CARBON TETRACHLORIDE; CYTOCHROME C OXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; SILYMARIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; CORRELATIONAL STUDY; COX6A2 GENE; COX7A1 GENE; COX8B GENE; DNA MICROARRAY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER FIBROSIS; LIVER PROTECTION; MARKER GENE; MOUSE; NONHUMAN; STAINING; TRANSCRIPTOMICS; TRANSGENIC MOUSE;

ANIMALS; BASE SEQUENCE; CARBON TETRACHLORIDE; DNA PRIMERS; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LUMINESCENCE; MICE; MICE, TRANSGENIC; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; SILYMARIN; TRANSCRIPTOME;

MUS; MUS MUSCULUS;

EID: 84862807386     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.02.025     Document Type: Article

References (51)

1. Abenavoli L., Capasso R., Milic N., Capasso F. Milk thistle in liver diseases: past, present, future. Phytother. Res. 2010, 24:1423-1432.
2. Ai W., Zhang Y., Tang Q.Z., Yan L., Bian Z.Y., Liu C., Huang H., Bai X., Yin L., Li H. Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling. J. Cell Biochem. 2010, 110:1111-1122.
3. Baeuerle P.A., Baichwal V.R. NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv. Immunol. 1997, 65:111-137.
4. Baldwin A.S. The NF-κB and IκB proteins: new discoveries and insights. Annu. Rev. Immunol. 1996, 14:649-683.
5. Basiglio C.L., Sanchez Pozzi E.J., Mottino A.D., Roma M.G. Differential effects of silymarin and its active component silibinin on plasma membrane stability and hepatocellular lysis. Chem. Biol. Interact 2009, 179:297-303.
6. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005, 115:209-218.
7. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., Pistell P.J., Poosala S., Becker K.G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K.W., Spencer R.G., Lakatta E.G., Le Couteur D., Shaw R.J., Navas P., Puigserver P., Ingram D.K., de Cabo R., Sinclair D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
8. Bonizzi G., Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004, 25:280-288.
9. Boyer P.D. The ATP synthase - a splendid molecular machine. Annu. Rev. Biochem. 1997, 66:717-749.
10. Chandan B.K., Saxena A.K., Shukla S., Sharma N., Gupta D.K., Singh K., Suri J., Bhadauria M., Qazi G.N. Hepatoprotective activity of Woodfordia fruticosa Kurz flowers against carbon tetrachloride induced hepatotoxicity. J. Ethnopharmacol. 2008, 119:218-224.
11. Chang C.T., Lin H., Ho T.Y., Li C.C., Lo H.Y., Wu S.L., Huang Y.F., Liang J.A., Hsiang C.Y. Comprehensive assessment of host responses to ionizing radiation by nuclear factor-κB bioluminescence imaging-guided transcriptomic analysis. PLoS One 2011, 6:e23682.
12. 2+ release. Life Sci. 1988, 43:975-981.
13. Cheng H.M., Li C.C., Chen C.Y., Lo H.Y., Cheng W.Y., Lee C.H., Yang S.Z., Wu S.L., Hsiang C.Y., Ho T.Y. Application of bioactivity database of Chinese herbal medicine on the therapeutic prediction, drug development, and safety evaluation. J. Ethnopharmacol. 2010, 132:429-437.
14. Comporti M., Arezzini B., Signorini C., Vecchio D., Gardi C. Oxidative stress, isoprostanes and hepatic fibrosis. Histol. Histopathol. 2009, 24:893-900.
15. Contag C.H., Bachmann M.H. Advances in in vivo bioluminescence imaging of gene expression. Annu. Rev. Biomed. Eng. 2002, 4:235-260.
16. De Minicis S., Seki E., Uchinami H., Kluwe J., Zhang Y., Brenner D.A., Schwabe R.F. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 2007, 132:1937-1946.
17. Dothager R.S., Flentie K., Moss B., Pan M.H., Kesarwala A., Piwnica-Worms D. Advances in bioluminescence imaging of live animal models. Curr. Opin. Biotechnol. 2009, 20:45-53.
18. Hellerbrand C., Stefanovic B., Giordano F., Burchardt E.R., Brenner D.A. The role of TGFβ1 in initiating hepatic stellate cell activation in vivo. J. Hepatol. 1999, 30:77-87.
19. Ho T.Y., Chen Y.S., Hsiang C.Y. Noninvasive nuclear factor-κB bioluminescence imaging for the assessment of host-biomaterial interaction in transgenic mice. Biomaterials 2007, 28:4370-4377.
20. Hseu Y.C., Huang H.C., Hsiang C.Y. Antrodia camphorata suppresses lipopolysaccharide-induced nuclear factor-κB activation in transgenic mice evaluated by bioluminescence imaging. Food Chem. Toxicol. 2011, 48:2319-2325.
21. Hsiang C.Y., Chen Y.S., Ho T.Y. Nuclear factor-κB bioluminescence imaging-guided transcriptomic analysis for the assessment of host-biomaterial interaction in vivo. Biomaterials 2009, 30:3042-3049.
22. Jia J.D., Bauer M., Cho J.J., Ruehl M., Milani S., Boigk G., Riecken E.O., Schuppan D. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J. Hepatol. 2001, 35:392-398.
23. Jimenez W., Pares A., Caballeria J., Heredia D., Bruguera M., Torres M., Rojkind M., Rodes J. Measurement of fibrosis in needle liver biopsies: evaluation of a colorimetric method. Hepatology 1985, 5:815-818.
24. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 2000, 18:621-663.
25. Krahenbuhl S., Reichen J. Adaptation of mitochondrial metabolism in liver cirrhosis. Different strategies to maintain a vital function. Scand. J. Gastroenterol. Suppl. 1992, 193:90-96.
26. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., Lerner J., Brunet J.P., Subramanian A., Ross K.N., Reich M., Hieronymus H., Wei G., Armstrong S.A., Haggarty S.J., Clemons P.A., Wei R., Carr S.A., Lander E.S., Golub T.R. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935.
27. Lopez-De Leon A., Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J. Histochem. Cytochem. 1985, 33:737-743.
28. Lotersztajn S., Julien B., Teixeira-Clerc F., Grenard P., Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu. Rev. Pharmacol. Toxicol. 2005, 45:605-628.
29. Luedde T., Schwabe R.F. NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat. Rev. Gastroenterol Hepatol. 2011, 8:108-118.
30. Montaner D., Tarraga J., Huerta-Cepas J., Burguet J., Vaquerizas J.M., Conde L., Minguez P., Vera J., Mukherjee S., Valls J., Pujana M.A., Alloza E., Herrero J., Al-Shahrour F., Dopazo J. Next station in microarray data analysis: GEPAS. Nucleic Acids Res. 2006, 34:W486-W491.
31. Nanji A.A., Jokelainen K., Tipoe G.L., Rahemtulla A., Dannenberg A.J. Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration. J. Pharmacol. Exp. Ther. 2001, 299:638-644.
32. Ottobrini L., Lucignani G., Clerici M., Rescigno M. Assessing cell trafficking by noninvasive imaging techniques: applications in experimental tumor immunology. Q. J. Nucl. Med. Mol. Imaging 2005, 49:361-366.
33. Pietrangelo A., Montosi G., Garuti C., Contri M., Giovannini F., Ceccarelli D., Masini A. Iron-induced oxidant stress in nonparenchymal liver cells: mitochondrial derangement and fibrosis in acutely iron-dosed gerbils and its prevention by silybin. J. Bioenerg. Biomembr. 2002, 34:67-79.
34. Polyak S.J., Morishima C., Shuhart M.C., Wang C.C., Liu Y., Lee D.Y. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-κB signaling, and HCV infection by standardized Silymarin. Gastroenterology 2007, 132:1925-1936.
35. Pradhan S.C., Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Ind. J. Med. Res. 2006, 124:491-504.
36. 4-induced liver fibrosis in mice. Hepatology 2004, 40:1304-1311.
37. Saller R., Meier R., Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001, 61:2035-2063.
38. Sarraf-Yazdi S., Mi J., Dewhirst M.W., Clary B.M. Use of in vivo bioluminescence imaging to predict hepatic tumor burden in mice. J. Surg. Res. 2004, 120:249-255.
39. Shaker, E., Mahmoud, H., Mnaa, S., 2010. Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage. Food Chem. Toxicol. 48, 803-806.
40. 4 and alcohol induced hepatitis in rats and their correction with simvastatin. J. Bioenerg. Biomembr. 2008, 40:27-34.
41. Siebenlist U., Franzoso G., Brown K. Structure, regulation and function of NF-κB. Annu. Rev. Cell Biol. 1994, 10:405-455.
42. 4 liver fibrosis model in rats. Eur. J. Pharmacol. 2010, 631:53-60.
43. Suter L., Babiss L.E., Wheeldon E.B. Toxicogenomics in predictive toxicology in drug development. Chem. Biol. 2004, 11:161-171.
44. Tacke F., Wustefeld T., Horn R., Luedde T., Srinivas Rao A., Manns M.P., Trautwein C., Brabant G. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J. Hepatol. 2005, 42:666-673.
45. Tanaka A., Morimoto T., Wakashiro S., Ikai I., Ozawa K., Orii Y. Kinetic alterations of cytochrome c oxidase in carbon tetrachloride induced cirrhotic rat liver. Life Sci. 1987, 41:741-748.
46. Upadhyay G., Tiwari M.N., Prakash O., Jyoti A., Shanker R., Singh M.P. Involvement of multiple molecular events in pyrogallol-induced hepatotoxicity and silymarin-mediated protection: evidence from gene expression profiles. Food Chem. Toxicol. 2010, 48:1660-1670.
47. Weber L.W., Boll M., Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol. 2003, 33:105-136.
48. Weiler-Normann C., Herkel J., Lohse A.W. Mouse models of liver fibrosis. Z. Gastroenterol. 2007, 45:43-50.
49. Wells R.G. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J. Clin. Gastroenterol. 2005, 39:S158-S161.
50. Wu S.L., Chen J.C., Li C.C., Lo H.Y., Ho T.Y., Hsiang C.Y. Vanillin improves and prevents trinitrobenzene sulfonic acid-induced colitis in mice. J. Pharmacol. Exp. Ther. 2009, 330:370-376.
51. Xiong Y.Q., Willard J., Kadurugamuwa J.L., Yu J., Francis K.P., Bayer A.S. Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis model. Antimicrob Agents Chemother. 2005, 49:380-387.